Skip to main content
SpringerLink
Log in

Minority Women and Cardiovascular Disease

  • Chapter
Cardiovascular Disease in Racial and Ethnic Minorities

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Large epidemiological studies have helped define differences in majority and minority population health risks and outcomes. The National Health and Nutrition Examination Survey (NHANES) observed African-American, Mexican American, and white non-Hispanic women from 1988 to 1994 and found a striking prevalence of abdominal obesity and metabolic syndrome in both African-Americans and Mexican Americans. The Multi-Ethnic Study of Atherosclerosis (MESA) was designed to study the prevalence and progression of sub-clinical CVD in multiple ethnicities including whites. The rate of awareness of CVD as the leading cause of death has nearly doubled among women since 1997. Awareness of heart disease is independently correlated with increased physical activity and weight loss. The NHANES study shows that the prevalence of obesity, which can be associated with insulin resistance, is highest in non-Hispanic black women.

The Women’s Health Initiative (WHI) has shown that the major correlates of HTN among postmenopausal women were black race, CVD, physical inactivity, and excess alcohol consumption. There was also evidence that blood pressure control decreased with age. The Dallas Heart Study has shown that left ventricular hypertrophy (LVH) is two- to three-fold more common in African-American women compared to Caucasian women. About 30% of women in America do not perform any leisure-time physical activity (Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/data/nhis/earlyrelease/200709_07.pdf;). This percentage is higher in women with less than a high school education or lower income groups. Women respond better to lifestyle physical activity recommendations vs structured exercise recommendations. For many women, a home-based format for physical activity which would accommodate their caregiver and work roles would be more advantageous over more traditional sessions in a gym or health club.

When adjustment for lipids, diabetes, and HTN were made, elevated levels of CRP still remained a predictor of increase risk of CAD with a RR Of 1.68 (Pai et al. N Engl J Med 351:2599–2610, 2004). Anemia, which is much more prevalent in women, is associated with adverse CV consequences by increasing preload and reducing afterload and in the long term, resulting in LVH. The WHS found no benefit of adding 600 IU of vitamin E supplementation every other day on reduction of major CV events or cancer, as well as overall survival benefits; The Primary Prevention Project enrolled 4495 patients (2583 women with a mean age of 64.4 years) with one or more risk factors for CVD. This trial found that 100 mg of aspirin/day lowered CV death by 44% and total CV events by 23%. By contrast, the WHS found that in healthy women 45 years and above, 100 mg of aspirin every other day did not affect the risk of myocardial infarction or death from CV causes but lowered the risk of stroke. Compared to the WHS, the Primary Prevention Project was an open label study which enrolled older patients (mean age 64.4 years compared to 54.6 in WHS), with at least one CV risk. These factors may explain the variable effect of aspirin found in these two studies.

Multiple observational studies suggested that estrogen replacement in postmenopausal women decreased heart disease risk by 50%. However, new randomized studies have addressed the issue of hormone replacement in menopausal women. Exercise electrocardiographic evaluation has lower sensitivity and specificity in detecting obstructive CAD in women: 61 and 70% as compared to 70 and 77% in men. Despite this, prognostic information can be derived from exercise testing. Exercise duration is the strongest predictor of long-term outcomes. Because of the limitations of exercise stress electrocardiography in women, concomitant imaging has been tested. The positive predictive value is lower in women compared to men (66% vs 84%) which may be a reflection of the lower prevalence of obstructive CAD in women who were tested. Pharmacologic stress testing such as dobutamine stress echocardiography (DSE) can be done in patients that cannot exercise. Women who cannot exercise should undergo pharmacologic stress testing or dobutamine echocardiography, which has the highest combination of sensitivity and specificity. Cardiovascular disease in women is very unique in that there is greater symptom burden, despite a lower prevalence of obstructive CAD by coronary angiography as compared to men. The pathophysiology of chest pain with non-obstructive epicardial CAD is very variable. Some patients have non-cardiac chest pain, while others have endothelial dysfunction, variant angina, or an overlap of these conditions. Even though women bear about 50% of the burden of heart failure in the United States, their representation in the randomized controlled heart failure trials has been about 20% and it has not changed over the past two decades.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosamond W, Flega K, Friday G, et al., for the American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics—2007 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5):e69–e171.

    Article  PubMed  Google Scholar 

  2. Winkleby MA, Kraemer HC, Ahn DK, et al. Ethnic and socioeconomic differences in cardiovascular disease risk factors: Findings for women from the Third National Health and Nutrition Examination Survey, 1988–1994. JAMA 1998; 280(4): 356–362.

    Article  CAS  PubMed  Google Scholar 

  3. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999; 99(18):2389–2395.

    Article  CAS  PubMed  Google Scholar 

  4. Bild DE, Deliano R, Peterson D. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005; 111(10):1313–1320.

    Article  PubMed  Google Scholar 

  5. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6):e85–e151.

    Article  PubMed  Google Scholar 

  6. Mosca L, Ferris A, Fabunmi R, et al. Tracking women’s awareness of heart disease: An American Heart Association National Study. Circulation 2004; 109(5):573–579.

    Article  PubMed  Google Scholar 

  7. DuBard CA, Garrett J, Gizlice Z. Effect of language on heart attack and stroke awareness among U.S. hispanics. Am J Prev Med 2006; 30(3):189–196.

    Article  PubMed  Google Scholar 

  8. Mosca L, Mochari H, Christian A, et al. National study of women’s awareness, preventive action, and barriers to cardiovascular health. Circulation 2006; 113(4):525–534.

    Article  PubMed  Google Scholar 

  9. Mosca L, Linfante AH, Benjamin EJ. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111(4):499–510.

    Article  PubMed  Google Scholar 

  10. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among U.S. children, adolescents, and adults, 1999–2002. JAMA 2004; 291(23):2847–2850.

    Article  CAS  PubMed  Google Scholar 

  11. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21(6):697–738.

    Article  CAS  PubMed  Google Scholar 

  12. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95(3):136–147.

    Article  CAS  PubMed  Google Scholar 

  13. Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288(5):H2031–2041.

    Article  CAS  PubMed  Google Scholar 

  14. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation 2006; 113(25):e924–e929.

    Article  PubMed  Google Scholar 

  15. Powers DR, Wallin JD. End-Stage renal disease in specific ethnic and racial groups: Risk factors and benefit of antihypertensive therapy. Arch Intern Med 1998; 158(7):793–800.

    Article  CAS  PubMed  Google Scholar 

  16. Oparil S. Women and hypertension: what did we learn from the women’s health initiative? Cardiol Rev 2006; 14(6):267–275.

    Article  PubMed  Google Scholar 

  17. Wright JT. Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293(13):1595–1608.

    Article  CAS  PubMed  Google Scholar 

  18. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Study on Hypertension in Blacks. Arch Intern Med 2003; 163(5):525–541.

    Article  PubMed  Google Scholar 

  19. Drazner MH, Dries DL, Peschock RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: The Dallas Heart Study. Hypertension 2005; 46(1):124–129.

    Article  CAS  PubMed  Google Scholar 

  20. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322(22):1561–1566.

    Article  CAS  PubMed  Google Scholar 

  21. Drazner MH, Rame JE, Marino EK, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43(12):2207–2215.

    Article  PubMed  Google Scholar 

  22. Lee WL, Cheung AM, Cape D, et al. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000; 23(7):962–968.

    Article  CAS  PubMed  Google Scholar 

  23. Franco OH, Steyerberg EW, Hu FB. Associations of diabetes mellitus with total life expectancy with and without cardiovascular disease. Arch Intern Med 2007; 167(11):1145–1151.

    Article  PubMed  Google Scholar 

  24. Steinberg HO, Paradisi G, Cronin J, et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 2000; 101(17): 2040–2046.

    Article  CAS  PubMed  Google Scholar 

  25. Koh KK, Kang MH, Jin DK, et al. Vascular effects of estrogen in type II diabetic postmenopausal women. JACC 2001; 38(5):1409–1415.

    Article  CAS  PubMed  Google Scholar 

  26. Wexler DJ, Grant RW, Meigs JB, et al. Sex disparities in treatment of cardiac risk factors in patients with type II diabetes. Diabet Care 2005; 28(3):514–520.

    Article  Google Scholar 

  27. Centers for Disease Control and Prevention. Smoking and tobacco use. (Accessed September 2007 at http://www.cdc.gov/tobacco)

  28. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. NEJM 1987; 317(21):1303–1309.

    Article  CAS  PubMed  Google Scholar 

  29. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994; 154(2):169–175.

    Article  CAS  PubMed  Google Scholar 

  30. Kaur S, Cohen A, Color R, et al. The impact of environmental tobacco smoke on women’s risk of dying from heart disease: a Meta-Analysis. J Womens Health (Larchmt) 2004; 13(8):888–897.

    Article  Google Scholar 

  31. Centers for Disease Control and Prevention. early release of selected estimates based on data from the 2007 National health interview survey. (Accessed September 14, 2008 at http://www.cdc.gov/nchs/data/nhis/earlyrelease/200709_07.pdf)

  32. Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women: a statement for healthcare professionals from the American heart association writing group. Circulation 1997; 96(7):2468–2482.

    Article  CAS  PubMed  Google Scholar 

  33. Lemaitre RN, Heckbert SR, Psaty BM, et al. Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch Intern Med 1995; 155(21):2302–2308.

    Article  CAS  PubMed  Google Scholar 

  34. Krummel DA, Koffman DM, Bronner Y, et al. Cardiovascular health interventions in women: what works? J Womens Health Gend Based Med 2001; 10(2):117–136.

    Article  CAS  PubMed  Google Scholar 

  35. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently health women. Circulation 1998; 98(8):731–733.

    Article  CAS  PubMed  Google Scholar 

  36. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347(20):1557–1565.

    Article  CAS  PubMed  Google Scholar 

  37. Mora S, Ridker PM. Justification for the use of statin in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006; 97(2A):33A–41A.

    Article  CAS  PubMed  Google Scholar 

  38. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351(25):2599–2610.

    Article  CAS  PubMed  Google Scholar 

  39. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16(11):3403–3410.

    Article  PubMed  Google Scholar 

  40. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16(2):529–538.

    Article  PubMed  Google Scholar 

  41. Arant CB, Wessel TR, Olson MB, et al., for the National Heart, Lung, and Blood Institute Women’s Ischemia Syndrome Evaluation Study. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women’s Ischemia Syndrome Evaluation Study. J Am Coll Cardiol 2004; 43(11):2009–2014.

    Article  CAS  PubMed  Google Scholar 

  42. Tedeschi-Reiner E, Strozzi M, Skoric B, et al. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. Am J Cardiol 2005; 96(8):1107–1109.

    Article  PubMed  Google Scholar 

  43. Bressler NM. Retinal arteriolar narrowing and risk of coronary heart disease. Arch Ophthalmol 2003; 121(1):113–114.

    Article  PubMed  Google Scholar 

  44. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002; 287(9):1153–1159.

    Article  PubMed  Google Scholar 

  45. Palaniappan L, Anthony MN, Mahesh C, et al. Cardiovascular risk factors in ethnic minority women aged < or = 30 Years. Am J Cardiol 2002; 89(5):524–529.

    Article  PubMed  Google Scholar 

  46. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24(12):2219–2226.

    Article  CAS  PubMed  Google Scholar 

  47. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and Vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357(9250):89–95.

    Article  PubMed  Google Scholar 

  48. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the women’s health study: a randomized controlled trial. JAMA 2005; 294(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  49. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13):1293–1304.

    Article  CAS  PubMed  Google Scholar 

  50. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295(3):306–313.

    Article  CAS  PubMed  Google Scholar 

  51. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273(3):199–208.

    Google Scholar 

  52. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349(6):523–534.

    Article  CAS  PubMed  Google Scholar 

  53. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7):605–613.

    Article  CAS  PubMed  Google Scholar 

  54. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47(9):1741–1753.

    Article  CAS  PubMed  Google Scholar 

  55. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13):1465–1477.

    Article  CAS  PubMed  Google Scholar 

  56. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. the WISE Investigators. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006; 47(3 Suppl.):S4–S20.

    Article  PubMed  Google Scholar 

  57. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999; 83(5):660–666.

    Article  CAS  PubMed  Google Scholar 

  58. Lloyd GW, Patel NR, McGing E, et al. Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart 2000; 84(2): 189–192.

    Article  CAS  PubMed  Google Scholar 

  59. Shaw LJ, Olson MB, Kip K, et al. The value of estimated functional capacity in estimating outcome: results from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol 2006; 47(3 Suppl.):S36–S43.

    Article  PubMed  Google Scholar 

  60. Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290(12):1600–1607.

    Article  CAS  PubMed  Google Scholar 

  61. Pancholy SB, Fattah AA, Kamal AM, et al. Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women. J Nucl Cardiol 1995; 2:110–116.

    CAS  PubMed  Google Scholar 

  62. Hansen CL, Crabbe D, Rubin S. Lower diagnostic accuracy of Thallium-201 SPECT myocardial perfusion imaging in women: an effect of small chamber size. J Am Coll Cardiol 1996; 28(5):1214–1219.

    Article  CAS  PubMed  Google Scholar 

  63. Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 2000; 101(12):1465–1478.

    Article  CAS  PubMed  Google Scholar 

  64. Taillefer R, DePuey EG, Udelson JE, et al. Comparative diagnostic accuracy of TI-201 and Tc-99m Sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol 1997; 29(1):69–77.

    Article  CAS  PubMed  Google Scholar 

  65. Marwick TH, Shaw LJ, Lauer MS, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. Am J Med 1999; 106(2)172–178.

    Article  CAS  PubMed  Google Scholar 

  66. Boyne TS, Koplan BA, Parsons WJ, et al. Predicting adverse outcome with exercise SPECT Technetium-99m Sestamibi imaging in patients with suspected or known coronary artery disease. Am J Cardiol 1997; 79(3):270–274.

    Article  CAS  PubMed  Google Scholar 

  67. Arruda-Olson AM, Juracan EM, Mahoney DW, et al. Prognostic value of exercise echocardiography in 5798 patients: is there a gender difference? J Am Coll Cardiol 2002; 39(4):625–631.

    Article  PubMed  Google Scholar 

  68. Roger VL, Pellikka PA, Bell MR, et al. Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. Circulation 1997; 95(2):405–410.

    Article  CAS  PubMed  Google Scholar 

  69. Williams MJ, Marwick TH, O’Gorman D, et al. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women. Am J Cardiol 1994; 74(5):435–438.

    Article  CAS  PubMed  Google Scholar 

  70. Ho YL, Wu CC, Huang PJ, et al. Assessment of coronary artery disease in women by dobutamine stress echocardiography: comparison with stress Shallium-201 single-photon emission computed tomography and exercise electrocardiography. Am Heart J 1998; 135(4):655–662.

    Article  CAS  PubMed  Google Scholar 

  71. Kim C, Kwok YS, Heagerty P, et al. Pharmacologic stress testing for coronary disease diagnosis: a meta-analysis. Am Heart J 2001; 142(6):934–944.

    Article  CAS  PubMed  Google Scholar 

  72. Tong AT, Douglas PS. Stress echocardiography in women. Cardiol Clin 1999; 17(3):573–582.

    Article  CAS  PubMed  Google Scholar 

  73. Detrano R, Hsiai T, Wang, S, et al. Prognostic value of coronary calcification and angiographic stress stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996; 27(2):285–290.

    Article  CAS  PubMed  Google Scholar 

  74. Georgiou D, Budoff MJ, Kaufer E, et al. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol 2001; 38(1):105–110.

    Article  CAS  PubMed  Google Scholar 

  75. Manson JE, Allison MA, Rossouw JE, et al., for the WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356(25):2591–2602.

    Article  CAS  PubMed  Google Scholar 

  76. Becker A, Leber A, von Ziegler F, et al. Comparison of progression of coronary calcium in postmenopausal women on versus not on Estrogen/progestin therapy. Am J Cardiol 2007; 99(3):374–378.

    Article  CAS  PubMed  Google Scholar 

  77. Nasir K, Redberg RF, Budof MJ, et al. Utility of stress testing and coronary calcification measurement for detection of coronary artery disease in women. Arch Intern Med 2004; 164(15):1610–1620.

    Article  PubMed  Google Scholar 

  78. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999; 341(4):217–225.

    Article  CAS  PubMed  Google Scholar 

  79. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence high-risk coronary artery disease in patient subsets (CASS). Circulation 1981; 64(2):360–367.

    Article  CAS  PubMed  Google Scholar 

  80. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. global use of strategies to open occluded coronary arteries in acute coronary syndromes IIb investigators. N Engl J Med 1999; 341(4):226–232.

    Article  CAS  PubMed  Google Scholar 

  81. Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74(6):531–537.

    Article  CAS  PubMed  Google Scholar 

  82. Widlansky ME, Gokce N, Keaney JF, Jr, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42(7):1149–1160.

    Article  CAS  PubMed  Google Scholar 

  83. von Mering GO, Arant CB, Wessel TR, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109(6):722–725.

    Article  Google Scholar 

  84. Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 342(12):829–835.

    Article  CAS  PubMed  Google Scholar 

  85. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with Myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109(24):2993–2999.

    Article  PubMed  Google Scholar 

  86. Bugiardini R, Bairey Merz CN. Angina with “Normal” coronary arteries: a changing philosophy. JAMA 2005; 293(4):477–484.

    Article  CAS  PubMed  Google Scholar 

  87. Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004; 109(21):2518–2523.

    Article  PubMed  Google Scholar 

  88. Brown DW, Haldeman GA, Croft JB, et al. Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. Am Heart J 2005; 150(3):448–454.

    Article  PubMed  Google Scholar 

  89. Wilson PW. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Am J Cardiol 1997; 80(9B):3 J–8 J.

    Google Scholar 

  90. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340(8):609–616.

    Article  CAS  PubMed  Google Scholar 

  91. Adams KF, Jr, Dunlap SH, Sueta CA, et al. Relation between gender, etiology, and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996; 28(7):1781–1788.

    Article  PubMed  Google Scholar 

  92. Vaccarino V, Chen VT, Wang Y, et al. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J 1999; 138(5 Pt 1):835–842.

    Article  CAS  PubMed  Google Scholar 

  93. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296(18):2209–2216.

    Article  CAS  PubMed  Google Scholar 

  94. Yancy CW. Heart failure in African Americans: pathophysiology and treatment. J Card Fail 2003; 9(5 Suppl. Nitric Oxide):S210–S215.

    Article  CAS  PubMed  Google Scholar 

  95. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162(15):1682–1688.

    Article  PubMed  Google Scholar 

  96. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41(9):1529–1538.

    Article  CAS  PubMed  Google Scholar 

  97. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared to white patients with left ventricular dysfunction. N Engl J Med 2001; 344(18):1351–1357.

    Article  CAS  PubMed  Google Scholar 

  98. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347(18):1403–1411.

    Article  CAS  PubMed  Google Scholar 

  99. Adams KF, Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46(3):497–504.

    Article  CAS  PubMed  Google Scholar 

  100. Campia U, Choucair WK, Bryant MB, et al. Reduced endothelium-dependent and independent dilation of conductance arteries in African Americans. J Am Coll Cardiol 2002; 40(4):754–760.

    Article  CAS  PubMed  Google Scholar 

  101. Cardillo C, Kilcoyne CM, Cannon RO 3rd, et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999; 99(1):90–95.

    Article  CAS  PubMed  Google Scholar 

  102. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5(3):178–187.

    Article  CAS  PubMed  Google Scholar 

  103. Taylor A, Ziesche S, Yancy C, et al., for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20):2049–2057.

    Article  CAS  PubMed  Google Scholar 

  104. Taylor AL, Lindenfeld J, Ziesche S, et al., for the A-HeFT Investigators. Outcomes by gender in the African-American Heart Failure Trial. JACC 2006; 48(11):2263–2267.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Columbia University Medical Center, College of Physicians and Surgeons, New York, NY, USA

    A. L. Taylor MD

  2. University of Minnesota, Minneapolis, MN, USA

    L. Bellumkonda MBBS

Authors
  1. A. L. Taylor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Bellumkonda MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cardiology Division, Emory University, 5355 Hunter Road, Atlanta, GA, 30349, USA

    Keith C. Ferdinand MD

  2. Department of Internal Medicine, New Hanover Regional Medical Center, 212 Walnut Street, Wilmington, NC, 28401 #101, USA

    Annemarie Armani MD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Taylor, A.L., Bellumkonda, L. (2009). Minority Women and Cardiovascular Disease. In: Ferdinand, K.C., Armani, A. (eds) Cardiovascular Disease in Racial and Ethnic Minorities. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-410-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-410-0_15

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-981-9

  • Online ISBN: 978-1-59745-410-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation